Detailed results from ALSYMPCA phase III study with Al.
Poster title: Abstract #9: Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA).